Acute pulmonary exacerbations (aPEs) in patients with cystic fibrosis (CF) often result in incomplete recovery of lung function despite treatment, and are associated with lung function decline over time [1, 2] . Monitoring is therefore important to detect aPEs early and to track treatment responses. Recent studies testing pulmonary function with multiple breath washout (MBW) have shown that the Lung Clearance Index (LCI), the main outcome measure of MBW, is a sensitive tool to measure early changes in the CF lung [3, 4] . However, the potential role of MBW and LCI in more advanced CF lung disease is currently unclear. In fact, a recent study demonstrated heterogeneous responses in LCI, with a significant proportion of patients with CF showing worsening of LCI with treatment for aPEs [5] . Resolution of mucus plugging, resulting in recruitment of poorly ventilated areas of the lung to MBW, would potentially explain the discordant changes in pulmonary function testing by spirometry and LCI with treatment.
The study was approved by the research ethics board of the Hospital for Sick Children in Toronto, ON, Canada. Participants were recruited between May 2011 and November 2012 from children presenting to the CF outpatient department with clinical signs of a CF aPE requiring hospital admission and treatment with intravenous antibiotics. Following informed written consent from patients and/or caregivers, MRI of the chest was performed (1.5 Tesla scanner; Avanto; Siemens Medical Solutions, Erlangen, Germany). The study protocol included the following sequences: 1) ECG-gated steady state free precession localiser images in the three orthogonal planes; 2) T2-weighted BLADE sequence with periodically rotated overlapping parallel lines with enhanced reconstruction in axial and coronal orientations; and 3) T1-weighted volumetric interpolated breath-hold examination (VIBE) before and after injection of gadopentetate dimeglumine (Magnevist; Bayer, Leverkusen, Germany). Lung morphometry (bronchiectasis, airway thickening, mucus plugging, parenchyma and trapped air) was quantified using the previously published CF-MRI scoring method [7, 8] . CF-MRI is an adapted version of the Brody score for MRI. Each lung lobe was scored independently, and the lingula was evaluated as a sixth lobe. Scores were expressed as a percentage of the maximum score. MBW to determine LCI was performed using sulfur hexafluoride (SF 6 ) and a mass spectrometry-based apparatus (AMIS 2000; Innovision), as previously described [9] . Spirometry measures were analysed as percent predicted. MRI, followed by MBW and spirometry, was performed within 48 h of admission and after 12 days (range 9-16 days) of intravenous antibiotics for aPEs, respectively.
The study population was summarised using parametric methods for normally distributed data and nonparametric methods for skewed data where necessary. Comparisons before and after treatment were made using paired t-tests. Correlations between MRI and LCI outcomes at pre-and post-treatment time points, as well as correlations between the changes in outcomes, were assessed using Pearson's correlation coefficient.
In total, 13 patients (seven male, six female) underwent MRI before and after antibiotic treatment for aPE. Mean age of the study participants was 13.5 years (range 7.8-17.4 years). Mean±SD forced expiratory volume in 1 second (FEV1) was 67±16% before treatment, and increased to 74±14% after treatment (Δ7%, 95% CI 2-12%; p=0.01). Improvement was also seen for forced vital capacity (FVC) ( p=0.04), FEV1/FVC ( p=0.05) and forced expiratory flows at mid lung volumes (FEF25-75) ( p=0.05). CF-MRI scores before and after treatment are given in table 1.
CF-MRI scores improved significantly for mucus plugging (Δ-3.5, 95% CI −5.4 to −1.5; p=0.002) and air trapping (Δ-2.5, 95% CI −4.7 to −0.3; p=0.03), whereas no significant changes were seen for bronchiectasis ( p=0.96), airway thickening ( p=0.27), parenchyma ( p=0.49) or total lung score ( p=0.09).
Of the 13 patients who underwent MRI, eight had research-quality MBW measured before and after treatment. Mean±SD LCI score was 12.4±2.3 before treatment, and did not change with treatment (Δ-0.2, 95% CI −1.1 to 0.7; p=0.59). LCI before treatment was positively correlated with CF-MRI total lung score (r=0.64; p=0.06), mucus plugging score (r=0.72; p=0.03) and bronchiectasis score (r=0.70; p=0.04). However, there was an inverse correlation between changes in LCI and changes in CF-MRI total lung score (r=−0.85; p<0.01). Significant negative correlations suggested worsening of LCI (increase in LCI) with improvement in mucus plugging (r=−0.74; p=0.04) and air trapping (r=−0.79; p=0.02) after therapy (decrease in CF-MRI scores) (figure 1). There was no correlation between changes in MRI scores and changes in spirometry with therapy.
Consistent with previous studies, MRI can be used to quantify lung disease severity in children with CF, and measures of lung function by LCI correlated with CF-MRI scores at the time of aPE. Interestingly, there was considerable individual variability in response to treatment in both CF-MRI scores and LCI. However, in this study, CF-MRI scoring of improved mucus plugging and trapped air following treatment of aPE correlated with worsening LCI. This observation may be best explained by recruitment of poorly ventilated areas of the lung through improvement of mucus plugging with treatment, leading to worsening in LCI. This is consistent with the heterogeneous responses in LCI during treatment of pulmonary exacerbations in older children, which we reported previously [5] . Interestingly, a recent study in children with CF found a more consistent pattern of improvement in LCI with treatment of aPE [4] . Their study included younger children with better pulmonary function and therefore probably less structural lung damage, for whom the net effect of reducing mucus plugging is more likely to improve ventilation homogeneity. While other factors than age and disease severity may contribute to the discrepant results in the two studies, these data would support the concept that LCI as a measure of treatment response may be less informative in individuals with significant airflow obstruction compared with those with early airway disease, as previously suggested [10] .
A limitation of our study is the relatively small sample size of patients who had both MRI and LCI measurements performed before and after treatment for aPE. Our findings therefore need to be interpreted with caution and confirmed in a larger population. Further studies are also needed to clarify the role of MBW and chest imaging techniques such as MRI for monitoring treatment responses other than those to antibiotics for aPEs in patients with CF and moderate to severe lung disease.
